PHILADELPHIA, March 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Jeffrey D. Marrazzo, chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference, on Monday, March 6, at 3:20 p.m. EST, at the Boston Marriott Copley Place in Boston.
An audio recording of Marrazzo’s presentation will be available on the "Events" section of sparktx.com/investors-media for 90 days following the conference. To access his presentation slide deck, please visit "Investor Presentations" on the Investors page.
Company management also will present at the Barclays Global Healthcare Conference, on Wednesday, March 15, at 4:20 p.m. EST, at the Loews Miami Beach Hotel in Miami.
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of biallelic RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 (which also has received both breakthrough therapy and orphan product designations) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.
Investor Relations Contact:
Monique da Silva
Spark Therapeutics, Inc.